论文部分内容阅读
Background MicroRNAs have recently been considered as biomarkers in several different cardiovascular diseases,however,so far there are no circulating miRNAs data about hypertension.Therefore,the aim of the present pilot study was to identify circulating miRNAs for hypertension biomarkers.Methods Using an Agilent microarray,plasma miRNAs were profiled from plasma samples of 10 patients with untreated essential hypertension and 10 healthy controls.Candidate biomarkers identified in the profiles were subjected to validation by using quantitative PCR in an independent sample set of 20 patients with untreated essential hypertension and 20 healthy controls.Then,we assessed the selected miRNAs for the detection and diagnosis of hypertension from plasma samples of 70 patients with untreated essential hypertension and 20 healthy controls.The Spearman correlation coefficient was used to assessed the selected miRNAs correlations with blood pressure.The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.Results The expressions of selected 8 miRNAs were investigated independently in plasma samples from 10 hypertension patients and 10 healthy subjects.The levels of circulating miR-30c-5p,miR-133b,miR-29b-3p,miR-29a-3p,miR-29c-3p,miR-30a-3p,miR-let7b-3p expression were significantly down regulated in hypertension group compared with healthy group and the level of hsa-iR-92b-3p was significantly unregulated between the groups.We used qRT-PCR assay to confirm the expression of 8 candidate miRNAs,miR-30c-5p (P ＜ 0.001),miR-29b-3p (P ＜ 0.001),miR-29a -3p (P =0.027),miR-29c-3p (P ＜ 0.001),miR-92b-3p (P =0.003),miR-30a-3p (P =0.704),miR-133b (P =0.346),andmiR-let7b (P =0.161).The diagnostic accuracy of miR-30c-5p,miR-29b-3p,miR-29a-3p,miR-29c-3p and miR-92b-3p,as measured by AUC,were 0.897,0.90,0.829,0.825 and 0.832,respectively,with all P ＜0.001.Conclusions The plasma levels of miR-30c-5p,miR-29b-3p,miR-29a-3p,miR-29c-3p and miR-92b-3p associated with hypertension which provide an impetus for future evaluations of hypertension development,progression,therapeutic efficacy and prognosis.